Med Tech-related technology assessments from NICE in May 2025

Health Technology Evaluations (HTE) using the Early Value Assessment (EVA) approach are the new type of NICE guidance to provide rapid conditional recommendations on promising health technologies that have the potential to address unmet national needs. NICE evaluates the available evidence to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated.

In May 2025, NICE published two new EVAs on Digital therapy for chronic tic disorders and Tourette syndrome and Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway and made the following conclusions:

• Online Remote Behavioural Intervention for Tics, ORBIT (Mindtech), can be used with standard care in the NHS during the evidence-generation period as an option to treat chronic tic disorders and Tourette syndrome in children and young people aged 9 to 17 years. More evidence is needed to assess the long-term clinical and cost-effectiveness, quality-of-life impact, adherence, natural disease progression without the technology, adverse events, subgroup-specific outcomes, and perspectives from individuals with tic disorders or Tourette syndrome and their carers. The second technology under the scope, Neupulse (Neurotherapeutics), is currently under development for over-the-counter sales, is awaiting CE and UKCA marking approval, and cannot be used or included in the NICE recommendations.
• Deep Ensemble for Recognition of Malignancy, DERM (by Skin Analytics), can be used within teledermatology services in the NHS during the evidence generation period as an option to assess and triage skin lesions in adults referred to the urgent suspected skin cancer pathway. NICE excluded Moleanalyzer pro (by FotoFinder Systems) from this assessment because it is intended to evaluate pigmented lesions to support biopsy decisions, not for triaging cases in urgent suspected skin cancer pathways.

Health Technology Evaluation with the Late Stage Assessment (LSA) approach aims to assess technologies that are in widespread or established use in the NHS to inform commissioning and procurement decisions. LSA evaluates whether incremental technological innovations within a category provide justifiable value for money, addressing the inconsistency in how such advancements are typically recognized and valued.

In May 2025, NICE published one new LSA on Drug-eluting stents for treating coronary artery disease. It was concluded that there is not enough evidence comparing drug-eluting stents to determine whether price variation between different stents is justified. NHS trusts should provide access to a range of drug-eluting stents so that a clinically appropriate stent is available for everyone with coronary artery disease. If more than one drug-eluting stent is clinically appropriate, the least expensive stent should be chosen.

Furthermore, in May 2025, NICE updated three clinical guidelines on Abortion care, Suspected cancer: recognition and referral, and COVID-19 rapid guideline: managing COVID-19.

See the full details in English here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.